RC1416
- Generic Name
- RC1416
A Phase Ib Study of RC1416 Injection
Phase 1
Not yet recruiting
- Conditions
- Moderate to Severe Asthma
- Interventions
- Drug: RC1416 Placebo
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06911866
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Shenzhen People's Hospital, Shenzhen, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath